Join
Live feed
·
PRReleasevia Quantisnow
Xenetic Biosciences Inc. logo

Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities

ByQuantisnow·Wall Street's wire, on your screen.
XBIO· Xenetic Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XBIO (Xenetic Biosciences Inc.) and more on Quantisnow.